A. Loewenstein ISRAEL

11:00 Welcome

P. Barreto PORTUGAL

11:02 Association of genetics and the adherence to the Mediterranean diet: the risk for age-related macular degeneration

A. Loewenstein ISRAEL

11:08 Efficacy and Safety of a Novel Ranibizumab Biosimilar Versus Reference Ranibizumab (Lucentis®) in Neovascular Age-Related Macular Degeneration

A. Rachitskaya USA

11:14 End-of-Study Retinal Fluid and Vision Outcomes in the Phase 3 Archway Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

A. Khanani USA

11:20 Suprachoroidal Delivery of RGX-314 Gene Therapy for Neovascular AMD: The Phase II AAVIATE® Study

T. Lai HONG KONG

11:32 Faricimab in Neovascular Age-Related Macular Degeneration: 48-Week Results by Dosing Interval Cohort in the Phase 3 TENAYA and LUCERNE Trials

B. Tombolini ITALY

11:38 OCT-A characterization of evolving lesions in fellow eyes of exudative type 3 MNV patients

T. Tibaldi ITALY

11:44 A comparison between two automated algorithms to segment the inner and outer retinal thicknesses in eyes with neovascular age-related macular degeneration.

D. Jack Fu JUK

11:50 Amalric triangular sign and carotid Doppler findings in central retinal artery occlusion

A. Antropoli ITALY

11:50 Optical Coherence Tomography features in Extensive Macular Atrophy with Pseudodrusen-like appearance versus Geographic Atrophy phenotypes

All Faculty

11:56 Discussion